Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Update

Altamira Therapeutics Ltd. (NASDAQ:CYTOGet Free Report) saw a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 128,800 shares, a growth of 27.4% from the May 15th total of 101,100 shares. Based on an average daily volume of 1,920,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 5.8% of the shares of the company are sold short.

Institutional Investors Weigh In On Altamira Therapeutics

A hedge fund recently bought a new stake in Altamira Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Altamira Therapeutics Ltd. (NASDAQ:CYTOFree Report) in the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 829,000 shares of the company’s stock, valued at approximately $203,000. Armistice Capital LLC owned approximately 11.86% of Altamira Therapeutics at the end of the most recent reporting period. 1.91% of the stock is owned by institutional investors and hedge funds.

Altamira Therapeutics Trading Up 2.5 %

CYTO stock traded up $0.03 during midday trading on Monday, reaching $1.24. 29,451 shares of the company’s stock traded hands, compared to its average volume of 1,156,225. The company has a 50-day moving average price of $1.56 and a two-hundred day moving average price of $2.44. Altamira Therapeutics has a 52 week low of $1.20 and a 52 week high of $17.20.

About Altamira Therapeutics

(Get Free Report)

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.

Featured Articles

Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with's FREE daily email newsletter.